rhTSH Stimulation Before Radioiodine Therapy in Thyroid Cancer Reduces the Effective Half-Life of 131I
Christian Menzel, MD, PhD,
Wolfgang T. Kranert, ScD,
Natascha Döbert, MD,
Michaela Diehl, MD,
Thomas Fietz, ScD,
Nadja Hamscho, MD,
Uwe Berner, MD and
Frank Grünwald, MD, PhD
Department of Nuclear Medicine, Hospital of the Johann W. Goethe University, Frankfurt, Germany
FIGURE 2. Comparative evaluation of mean TSH values (plus 1 SD) for different groups with and without rhTSH stimulation and corresponding mean hTG levels. From left to right, bars represent groups A, B, C, D, and E.
FIGURE 3. Effective half-life of therapeutic activities of radioiodine in patients after rhTSH stimulation (groups A and D) and after endogenous TSH stimulation (groups B, C, and E). From left to right, bars represent groups A, B, C, D, and E.